Table 3.
Yellow Fever Virus Serostatus and Geometric Mean Plaque-Reduction Neutralizing Titers (GMTs) in Infants, by Vaccines Received—Per-Protocol Population
| Variable | MV, YFV, MenAV, and PRV | MV, YFV, and MenAV | Difference, Percentage Points (95% CI) | ||
|---|---|---|---|---|---|
| Proportion | Percentage (95% CI) | Proportion | Percentage (95% CI) | ||
| Serologic finding | |||||
| Seroresponsea | |||||
| ≥4-fold increase | 141/293 | 48.1 (42.4–53.8) | 153/293 | 52.2 (46.5–57.9) | −4.1 (−12.2–4.0) |
| ≥2-fold increase | 202/293 | 68.9 (63.6–74.2) | 206/293 | 70.3 (65.1–75.5) | −1.4 (−8.8–6.1) |
| Seroconversionb | 210/287 | 73.2 (68.0–78.3) | 219/290 | 75.5 (70.6–80.5) | −2.3 (−9.5–4.8) |
| Time point | GMT (95% CI) | GMT (95% CI) | GMT Ratio (95% CI) | ||
| Baseline | 2.49 (2.37–2.62) | 2.40 (2.31–2.49) | … | ||
| Day 28 | 15.03 (13.31–16.97) | 16.82 (14.80–19.11) | 0.92c (.77–1.09) | ||
Abbreviations: CI, confidence interval; MenAV, meningococcal A conjugate vaccine; MV, measles vaccine; PRV, pentavalent rotavirus vaccine; YFV, yellow fever vaccine.
aDefined as the indicated fold increase in titer from baseline to day 28.
bDefined as seropositivity (titer, ≥1:8) at day 28 among participants who were seronegative (titer, <1:8) at baseline.
c P = .3150.